Sinha Sanjeev, Agarwal Ashish, Gupta Kartik, Mandal Dibyakanti, Jain Mitul, Detels Roger, Nandy Karabi, DeVos Michelle A, Sharma S K, Manoharan N, Julka P K, Rath G K, Ambinder Richard F, Mitsuyasu Ronald T
Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
Department of Epidemiology, UCLA School of Public Health, Los Angeles, CA, United States.
Curr HIV Res. 2018;16(4):315-320. doi: 10.2174/1570162X16666181018161616.
People living with HIV/AIDS are at an increased risk of developing cancer. The goals of this study were to obtain data on the prevalence of HIV in the cancer population and vice versa at a major tertiary cancer and HIV center in North India.
This cross-sectional study was conducted over a 3-year period from July 2013 to June 2016, wherein successive HIV positive patients from an anti-retroviral therapy (ART) center were screened for malignancy. Simultaneously, successive cancer patients at the cancer center were screened for HIV. Baseline demographic details, risk factors, and laboratory investigations were obtained for all the patients.
Among the 999 HIV-positive patients at the ART center, the prevalence of malignancy was 2% (n=20; 95% confidence interval (CI) 1.13, 2.87). Among the 998 patients with a malignancy, the prevalence of HIV infection was 0.9% (n=9; 95% CI 0.31, 1.49). Weight loss, loss of appetite, and fever were the most common symptoms in patients with HIV and cancer. Among 29 patients with HIV and cancer, AIDS-defining cancer was found in 19 patients; non-Hodgkin's lymphoma was the most common malignancy reported (n=13).
There is a low prevalence of HIV in cancer patients as well as a low prevalence of cancer in HIV patients. AIDS-defining cancers remain much more common than non-AIDS-defining cancers. With the increased coverage of ART, it is expected that non-AIDSdefining cancers will increase, as is evident from data from more developed countries.
感染艾滋病毒/艾滋病的人群患癌症的风险增加。本研究的目的是在印度北部一家主要的三级癌症与艾滋病毒中心获取癌症人群中艾滋病毒的流行数据，反之亦然。
这项横断面研究在2013年7月至2016年6月的3年期间进行，对来自抗逆转录病毒治疗（ART）中心的连续艾滋病毒阳性患者进行恶性肿瘤筛查。同时，对癌症中心的连续癌症患者进行艾滋病毒筛查。获取了所有患者的基线人口统计学细节、危险因素和实验室检查结果。
在ART中心的999名艾滋病毒阳性患者中，恶性肿瘤的患病率为2%（n = 20；95%置信区间（CI）1.13，2.87）。在998名患有恶性肿瘤的患者中，艾滋病毒感染的患病率为0.9%（n = 9；95% CI 0.31，1.49）。体重减轻、食欲不振和发热是艾滋病毒和癌症患者最常见的症状。在29名艾滋病毒和癌症患者中，19名患者被发现患有艾滋病界定的癌症；非霍奇金淋巴瘤是报告的最常见恶性肿瘤（n = 13）。
癌症患者中艾滋病毒的患病率较低，艾滋病毒患者中癌症的患病率也较低。艾滋病界定的癌症仍然比非艾滋病界定的癌症更为常见。随着抗逆转录病毒治疗覆盖率的提高，预计非艾滋病界定的癌症将会增加，正如来自更发达国家的数据所显示的那样。
